Anthera listing confirms weak IPO market

Date March 05, 2010

The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.

The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of  Omeros since it went public in October. Anthera and  Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list,  Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).

Investors still risk averse

Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.

As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.

US IPOs since window re-opened in second half of 2009 
Company  IPO Date  Raised ($m)  IPO Price ($)  Filed Price ($)  Average discount  Latest share price (4 Mar 10)  Share price performance since IPO 
  Cumberland Pharmaceuticals   10-Aug-09   85   17   19 - 21   -15%   11.47   -33% 
  Talecris Biotherapeutics   01-Oct-09   950   19   18 - 20   0%   21.24   12% 
  Omeros   08-Oct-09   70   10   10 - 12   -9%   5.98   -40% 
  Ironwood Pharmaceuticals   03-Feb-10   203   11.25   14 - 16   -25%   13.41   19% 
Anthera Pharmaceuticals    01-Mar-10   54   7   13 - 15   -50%   7.08   0% 
Averages           -20%     -8% 

In terms of how investors have reacted to these newly listed companies, it is no coincidence that the two stocks to gain in value, Talecris Biotherapeutics and  Ironwood, relate to two of the most mature companies with either marketed or pipeline products targeting niche markets or areas of unmet medical need.

Although Ironwood floated at a 25% discount to its proposed price, this price had been ambitiously raised by the company just prior to its IPO; the eventual amount raised of $203m was still higher than the $173m it had originally targeted when filing its  S-1 document in November.

Encouragement for Prometheus

Anthera’s IPO experience will not have encouraged many of the companies listed in the table below, particularly the likes of Aldagen who perhaps represent the ultimate high-risk investment (Aldagen flotation would be real test of investors' mettle, October 29, 2009).

Which just leaves Prometheus as the one company with the potential to launch a successful IPO attempt this year, without having to opt for a massive discount and its shares mostly likely to hold or gain value.

Group revenues reached $342m last year, over half of which was derived from sales of Entocort EC at $204m. However, the Crohn’s disease drug was licensed from  AstraZeneca five years ago and the deal is set to expire by the end of this year.

Until this contract is renegotiated it seems unlikely investors will accept such a high degree of uncertainty over the future of its most important drug.

Potential IPO candidates in the US  Count of Products by Status and Therapy Area 
Company  S-1 Date  Seeking to Raise  Company Founded  Marketed  Phase III  Phase II  Phase I  Pre-Clin  Research  R&D Therapy Area 
Prometheus Laboratories   19-Dec-07   $100m   31-Dec-95   8   -   1   -   -   -  GI:  1,   
Aveo Pharmaceuticals   16-Dec-09   $86m   19-Oct-01   -   1   1   1   4   2  Onco & Immuno:  9,    
Trius Therapeutics   06-Nov-09   $86m   30-Jun-04   -   -   1   -   2   -  Systemic anti-inf:  3,   
Aldagen   28-Oct-09   $81m   03-Mar-00   -   1   2   2   1   -  Cardio:  3,  Onco & Immuno:  3,    
Alimera Science   30-Oct-09   $80m   04-Jun-03   -   1   -   -   1   1  Sensory:  3,   
Tengion   24-Dec-09   $40m   10-Jul-03   -   -   1   1   3   1  GU: 4, GI: 1, Cardio: 1 

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2015 EP Vantage Ltd